三友医疗公告，公司拟以自有资金与韩国细基生物株式会社共同投资新设合资公司，研究创新细胞生物 材料等再生医学领域，注册资本为人民币6000万元，其中公司出资3960万元，占比66%。截止目前，公 司已完成新设公司的工商注册登记手续。本次对外投资已经公司总经理办公会审议通过，无需提交公司 董事会及股东大会审议。本次对外投资不构成关联交易，也不构成重大资产重组。 ...

Group 1: Financial Performance - The company achieved a record high revenue in 2024, but net profit declined significantly by -83.82% [2][4] - As of April 18, 2025, the number of registered shareholders was 16,423 [3] Group 2: Strategic Initiatives - The company plans to enhance operational management through various measures, including expanding chain pharmacy construction and developing a new model for specialized pharmacies [2][4] - Establishment of a wholly-owned subsidiary, Hunan Dajia Weikang Regenerative Medicine Research Institute, aims to strengthen capabilities in medical services and research [3][4] Group 3: Market Positioning - The company is focused on integrating online and offline services, creating a comprehensive health management ecosystem [4] - Efforts are being made to improve the efficiency of the pharmaceutical supply chain and expand market share in distribution [4] Group 4: Research and Development - The company is increasing investment in R&D for traditional Chinese medicine and innovative drugs, enhancing product quality and market competitiveness [4] - Collaboration with universities and hospitals is being pursued to advance research in regenerative medicine [3][4]

4月24日，冠昊生物今日收盘12.82元，上涨1.10%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到121.88倍，创15天以来新低，总市值33.99亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均46.75倍，行业中值29.99倍，冠昊生物排 名第110位。 股东方面，截至2025年4月18日，冠昊生物股东户数29448户，较上次减少722户，户均持股市值35.28万 元，户均持股数量2.76万股。 冠昊生物科技股份有限公司是一家从事再生医学材料及再生型医用植入器械研发、生产及销售的高科技 企业。公司主要从事研究、开发、生产:Ⅱ类、Ⅲ类:6846植入材料和人工器官,6846医用卫生材料及敷 料;销售自产产品及提供服务;三类、二类:植入材料和人工器官,医用卫生材料及敷料的批发、零售。公 司的技术研究和产品开发紧跟国家发展方向，目前公司参与了两项"十三五"国家重点研发计划，均是围 绕组织修复与可再生材料进行技术创新和新产品开发。 最新一期业绩显示，2025年一季报，公司实现营业收入9479.71万元，同比3.67%；净利润1486.61万 元，同比3.30%，销售毛利率77.05 ...

本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 证券代码：300238 证券简称：冠昊生物 公告编号：2025-020 一、重要提示 大信会计师事务所（特殊普通合伙）对本年度公司财务报告的审计意见为：标准的无保留意见。 本报告期会计师事务所变更情况：公司本年度会计师事务所为大信会计师事务所（特殊普通合伙）。 非标准审计意见提示 □适用 √不适用 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 □适用 √不适用 公司计划不派发现金红利，不送红股，不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 二、公司基本情况 1、公司简介 ■ 2、报告期主要业务或产品简介 公司上市时未盈利且目前未实现盈利 随着国家持续深化医疗改革，带量采购政策的稳步实施，不仅重塑了医疗器械、医药行业的竞争格局， 也为企业转型升级提供了重要契机。报告期内，公司持续加大研发创新力度，致力于开发具有自主知识 产权的新产品、新技术，将提升产品质量、优化产品结构视为 ...

证券之星消息，2025年4月22日和元生物(688238)发布公告称公司于2025年4月18日召开业绩说明会，国 泰海通证券、鹏华基金、招商基金、华安基金、银河基金、上银基金、博远基金、招银国际基金、肇万 资产、长见投资、勤远资产、中金公司（601995）、混沌道然资产、保银投资、中信证券、申万宏源证 券（000562）、兴业证券、东方证券、浙商证券（601878）、华西证券（002926）、天风证券 （601162）参与。 具体内容如下： 问：目前国内CGT行业需求和供给的变化情况如何，处于什么阶段，未来景气度恢复情况怎样？ 答：从政策方面，国家和各地产业发展继续加大对细胞和基因治疗领域的支持力度，出台一系列政策和 产业支持措施。同时，监管部门出台的一系列指南对于药物开发进一步规范，保障了行业长期健康发 展，促进了创新药对于高水平、高规格的CRO/CDMO需求。从技术和管线进度看，细胞和基因治疗领 域的相关产品正大规模走向临床，适应症从肿瘤领域向包括心血管、神经系统、血液学及自身免疫性疾 病等领域拓展。干细胞再生医学转化应用得到支持和推进，基因治疗商业化进程有里程碑式推进，如 2025年4月份，国内首款腺相 ...

国创联行：上周医药健康领域10起投融资，融资规模最高超亿元 炜璨医疗：完成数千万元天使轮融资 据人民日报健康客户端记者不完全统计，本周（2025年4月7日-4月11日）全国医药健康领域发生10起投融资事件。其中，一家企业挂牌新三板，两家企业 融资规模超亿元。 医药健康投融资周报 2025年4月7日-4月11日 | 序号 | 公司简称 | 融资金额 | 主要业务 | | --- | --- | --- | --- | | 1 | 容用民公 | 近亿元 | 再生医学领域的创新生物医药公司 | | 2 | 炜璨医疗 | 数千万元 | 微创植入式给药装置 (PORT) 的 新技术研发与应用 | | 3 | 中盛湖源 | 数千万元 | 开发iPSC衍生细胞治疗产品 | | 4 | 赛蕴生物 | 数千万元 | 靶向递送技术及其药物创新疗法研发 | | 5 | 觅投克生物 | 超千万元 | 老年宠物干细胞治疗药物及医疗技术开发 | | ട | 灵眸医疗 | 数千万元 | 计算机组织光学成像、硬件技术等 | | 7 | 爱连健康 | 未披露 | 健全多层次医疗保障体系建设 | | 8 | 斯坦德检测 | 未披露 | 检验检测 ...

Core Viewpoint - Zhenghai Biological's 2024 annual report reveals significant challenges, with a notable decline in both revenue and profit due to centralized procurement policies impacting key products [1][2]. Financial Performance - The company achieved an annual revenue of 363 million yuan, a year-on-year decrease of 12.19% [1]. - The net profit attributable to shareholders was 135 million yuan, down 29.49% year-on-year [1]. - The net profit after deducting non-recurring items was 113 million yuan, with a decline of 32.59%, marking the largest drop in five years [1]. - Quarterly performance showed a 17.83% decline in Q1 revenue, a reduced decline of 6.1% in Q2, and overall improvement in the second half, but not enough to reverse the annual downturn [1]. Impact of Centralized Procurement Policy - Centralized procurement policies have significantly affected the company's core products: oral repair membranes (48.3% of revenue) and absorbable dura mater patches (35.2% of revenue) [1]. - The price drop for dura mater patches reached 83.46% due to a six-province alliance, severely impacting revenue [1]. - The oral repair membrane's gross margin decreased by 2.73 percentage points, contributing to the decline in net profit [1][2]. Cost Control and Profitability - Despite revenue pressures, the company maintained a gross margin above 86%, with a slight year-on-year decrease of 3.96 percentage points [2]. - The net profit margin was 43.45%, still above the industry average, despite an 11.2% year-on-year decline [2]. - The company successfully mitigated some impacts of price reductions through supply chain optimization, showcasing strong cost control capabilities [2][4]. Cash Flow and Shareholder Returns - Operating cash flow net amount decreased by 7.77% year-on-year but remained positive, supporting dividend payments [2]. - Cumulative dividends since the company's listing reached 536 million yuan, with a dividend financing ratio of 2.29, indicating a strong commitment to shareholder returns [2]. Innovation and New Product Development - The company has been overly reliant on traditional products, with R&D expenses not significantly increasing as a percentage of revenue [3]. - New products like "Haiyu" active biological bone, which is the first domestic bone filling material containing rhBMP-2, represent a key opportunity for growth [3][4]. - The successful launch of "Haiyu" and ongoing projects like calcium silicate biological ceramic bone repair materials and breast patches could provide new revenue streams [3][4]. Strategic Adjustments - The company is adjusting its market strategy in response to centralized procurement pressures, including optimizing the supply chain and reducing sales expenses [4]. - The potential expansion of centralized procurement for oral repair membranes and dura mater patches in 2025 indicates ongoing pricing pressures [5]. - Despite a stock price decline of over 50% since 2023, the company announced a share buyback plan of 25 to 50 million yuan, reflecting management's confidence in long-term value [5].

近期，美国在全世界挥舞着关税大棒成为全球资本市场的焦点话题。在这一背景下，华熙生物的2024年 财报不仅关乎企业自身的发展轨迹，更成为观察中国生物科技企业在全球产业链中地位与韧性的重要窗 口。尽管财报数据显示公司业绩短期承压，但深入剖析其战略布局与科技投入，我们不难发现，华熙生 物正以一种更具前瞻性和战略定力的姿态，稳步迈向从"玻尿酸龙头"到"生命科学解决方案商"的华丽转 身，其在糖生物学与再生医学领域的深耕，更是为全球生物科技产业贡献了"中国方案"的新思路。 短期波动： 行业转型期的"成长之痛" 在全球经济风云变幻、国内消费市场深度调整的大背景下，华熙生物2024年财报数据的波动引发广泛关 注。财报数据显示，2024年华熙生物实现营业收入53.71亿元，同比下降11.61%；归属于上市公司股东的 净利润为1.74 亿元，下降70.59%。但拨开数据表象，深入探寻公司战略布局、行业发展趋势以及跨行业 创新融合的脉络，就会发现，这一短期波动实则是行业发展周期与企业自身战略转型叠加的必然结果。 当下，生命科学关联产业，如美妆护肤、医美等细分赛道，正经历从增量扩张向存量博弈的关键转变。 以功能性护肤品市场为例，全球 ...

Core Viewpoint - Huaxi Biological is undergoing a deep transformation in brand positioning and team philosophy, facing performance pressures while revealing new growth opportunities through foundational scientific research [1] Group 1: Financial Performance - In the 2024 financial report, Huaxi Biological reported a revenue decline of 11.61% to 5.371 billion yuan and a net profit decrease of 70.59% to 174 million yuan [2] - The company is currently in a crisis not solely due to performance decline but due to organizational entropy exceeding acceptable limits, necessitating significant internal restructuring [2] - Management changes, including organizational upgrades and a new compensation system, have incurred costs exceeding 70 million yuan, impacting short-term profits [2] Group 2: Strategic Investments - The company is increasing long-term strategic investments, including supply chain improvements and production efficiency enhancements, with related expenses exceeding 100 million yuan [3] - Continuous investment in forward-looking research and development is being made, focusing on emerging business areas such as regenerative medicine and nutritional science, with strategic innovation investments exceeding 100 million yuan [3] Group 3: Business Line Adjustments - The "Functional Skincare Business" has been rebranded as "Skin Science Innovation Transformation Business," which saw a revenue decline of 31.62% to 2.569 billion yuan, accounting for nearly 50% of main business revenue [4] - The company is restructuring brand positioning and scientific foundations for various brands, emphasizing a focus on scientific validation and team capability adjustments [4] Group 4: Growth Engines - The Nutritional Science Innovation Transformation Business (formerly Functional Food Business) experienced a significant revenue increase of 40.97% [5] - The medical terminal business grew over 30%, generating approximately 1.44 billion yuan, with skin-related medical products revenue reaching 1.073 billion yuan, a 43.57% increase [5] Group 5: Research Focus - Huaxi Biological is concentrating on foundational research in glycoscience and cell biology, aiming to translate scientific innovations into consumer-grade solutions [6][7] - The company has expanded the application of hyaluronic acid into new fields such as tissue engineering and targeted drug delivery, with ongoing research into the signaling mechanisms of glycan substances [9] Group 6: Future Directions - The company is committed to exploring aging intervention and regenerative medicine, with a focus on developing animal-free, serum-free cell culture media expected to launch in the second half of the year [16] - Huaxi Biological plans to leverage its research capabilities to create customized skincare products, with over 108 customization options validated scientifically [15]

报名：首届全球眼科大会 | 议程更新 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 合作伙伴征集：2025全球手术机器人大会 2025年3月26日，NMPA公布了创新医疗器械特别审查申请审查结果公示（2025年第3号），有 14款产品 进入创新通道。其中包括， 卓阮医疗科技（苏州）有限公 司 申请的" 生物疝修补补片 "。 # 揭开"基底膜"的神秘面纱 # 生物疝修补补片 材料来源 ：该产品由猪膀胱基底膜和猪小肠粘膜下层经过脱细胞处理、复合制成的 三明治结构补片 。 在机体的自我修复过程中，完整的BM对子宫内膜、皮肤、肌肉、角膜等组织功能性再生必不可少。如同机体内的天然BM的惊人诱导再生能力，BM产品植入后可 以快速促进机体细胞的黏附、迁移和分化，帮助组织特异性细胞定位并引导组织有序性再生，显著增强组织修复和伤口愈合，实现组织特异性再生。 超高生物活性 调节机体免疫应答，组织相容性高 降低瘢痕、降低粘连组织形成 减少并发症、远期力学强度稳定 有助于实现部分程度的特异性、功能性修复 结构特点 ：产品设计为" 粘膜下层+基底膜" 的仿生结构，具有贯穿孔，加速周围组织细胞长入，利于组 ...